他莫昔芬启动后的眼科就诊情况
这项回顾性队列研究基于All of Us数据,纳入2327名启动他莫昔芬治疗的成人,发现12个月内仅7.0%有眼科就诊,1.7%接受视网膜OCT或眼底照相。合并青光眼或糖尿病视网膜病变者就诊率更高(25.0% vs 6.3%)。在乳腺癌患者中,他莫昔芬使用与芳香化酶抑制剂相比,校正后12个月眼科就诊率无显著差异(aOR 1.10,95%CI 0.85-1.42)。
要点
- 他莫昔芬启动后12个月内眼科就诊率低(7.0%),视网膜专项检查更罕见(1.7%)。
- 合并青光眼或糖尿病视网膜病变者眼科就诊率显著更高(25.0% vs 6.3%)。
- 校正后他莫昔芬与芳香化酶抑制剂相比,眼科就诊率无显著差异(aOR 1.10)。
核心结论
- 他莫昔芬启动后眼科就诊不常见,视网膜专项检查罕见。
- 他莫昔芬使用与芳香化酶抑制剂使用相比,校正后12个月眼科就诊率无显著差异。
- 需更多关于视网膜病变发生率、自然史、筛查策略和临床获益的证据来指导指南。
研究设计与样本
- 回顾性队列研究,使用All of Us数据,最短随访365天。
- 纳入首次记录他莫昔芬处方的成人,排除使用羟氯喹者。
- 对照为患乳腺癌并使用芳香化酶抑制剂者。
主要发现
- 2327名他莫昔芬使用者中,162名(7.0%)在12个月内有一次眼科就诊,39名(1.7%)接受视网膜OCT或眼底照相。
- 合并青光眼或糖尿病视网膜病变者中88人有22人(25.0%)就诊,无合并症者2239人有140人(6.3%)就诊,差异18.7个百分点(95%CI 10.8-28.8,P<.001)。
- 既存青光眼(aOR 3.87,95%CI 2.12-7.06,P<.001)、索引前医疗使用更多(aOR 1.43,95%CI 1.24-1.63,P<.001)和年龄更大(每增加10岁aOR 1.21,95%CI 1.04-1.42,P=.02)与更高眼科使用相关。
- 乳腺癌患者中,他莫昔芬组1886人中126人(6.7%)就诊,芳香化酶抑制剂组2809人中240人(8.5%)就诊,差异-1.9个百分点(95%CI -3.4至-0.3,P=.02)。
- 校正后他莫昔芬使用与眼科使用增加无关(aOR 1.10,95%CI 0.85-1.42,P=.46)。
关键数值与推荐
- 主要结局为12个月内任何眼科就诊,通过眼检查、视网膜操作和眼访问代码识别。
- 次要结局为视网膜OCT或眼底照相。
- 比较他莫昔芬与芳香化酶抑制剂组时校正人口学、既存疾病、索引前医疗使用、地区和启动年份。
临床怎么用
- 他莫昔芬启动后眼科就诊率低,视网膜专项检查罕见,提示当前临床实践中缺乏系统筛查。
- 合并青光眼或糖尿病视网膜病变的患者眼科就诊率更高,可能反映既存眼病随访而非他莫昔芬特异性筛查。
- 他莫昔芬与芳香化酶抑制剂使用者的眼科就诊率无显著差异,不支持他莫昔芬导致额外眼科就诊负担。
- 需更多证据明确他莫昔芬视网膜病变的发生率和筛查策略,以指导临床指南制定。
局限性
- 研究为回顾性队列设计,可能存在未测量混杂。
- 眼科就诊通过代码识别,可能低估或误分类实际使用。
- 随访仅12个月,不足以评估长期视网膜毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tamoxifen can cause retinal toxicity and vision loss, yet no formal screening guideline exists in the US. OBJECTIVE: To characterize ophthalmic use after tamoxifen initiation, identify predictors, and compare 12-month use between those with breast cancer taking tamoxifen and those taking aromatase inhibitors. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted May to June 2026 using All of Us data with 365-day minimum follow-up. The setting was a US multisite research program. Participants included adults with a first tamoxifen prescription recorded in All of Us, excluding those taking hydroxychloroquine. The comparator included those with breast cancer taking aromatase inhibitors. EXPOSURES: Tamoxifen or aromatase inhibitor initiation. MAIN OUTCOMES AND MEASURES: The primary outcome was any ophthalmic encounter within 12 months, identified from eye examination, retinal procedure, and eye visit codes. Retinal optical coherence tomography (OCT) or fundus photography was secondary. Logistic regression assessed predictors and compared treatment groups after adjustment for demographics, preexisting conditions, preindex health care use, region, and initiation year. RESULTS: Among 2327 individuals taking tamoxifen (mean [SD] age, 53.8 [10.6] years; 2232 [95.9%] female), 162 (7.0%) had an ophthalmic encounter within 12 months, and 39 (1.7%) underwent retinal OCT or fundus photography. Among participants with preexisting glaucoma or diabetic retinopathy, 22 of 88 (25.0%) had an encounter vs 140 of 2239 (6.3%) without either condition (difference, 18.7 percentage points; 95% CI, 10.8-28.8 percentage points; P < .001). Preexisting glaucoma (adjusted odds ratio [aOR], 3.87; 95% CI, 2.12-7.06; P < .001), greater preindex health care use (aOR, 1.43; 95% CI, 1.24-1.63; P < .001), and older age (aOR per 10-year increase, 1.21; 95% CI, 1.04-1.42; P = .02) were associated with greater use. Among participants with breast cancer, 126 of 1886 individuals taking tamoxifen (6.7%) had an encounter vs 240 of 2809 individuals taking aromatase inhibitors (8.5%; difference, -1.9 percentage points; 95% CI, -3.4 to -0.3 percentage points; P = .02). After adjustment, tamoxifen use was not associated with greater ophthalmic use (aOR, 1.10; 95% CI, 0.85-1.42; P = .46). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that ophthalmic use after tamoxifen initiation was uncommon, and retinal-specific testing was rare. Tamoxifen use was not associated with greater adjusted 12-month use than aromatase inhibitor use. Additional evidence on retinopathy incidence, natural history, screening strategies, and clinical benefit is needed to inform guidance.
引用
- Gandhi, Balas, Wang, et al. Ophthalmic Encounters After Tamoxifen Initiation. JAMA Ophthalmol. 2026. PMID: 42955022. doi:10.1001/jamaophthalmol.2026.4646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。